Porcine Epidemic Diarrhoea Vaccines Market: By Type (Live Vaccines and Killed Vaccines); By Application (Piglets and Adults Pigs) and Geography

Porcine Epidemic Diarrhoea Vaccines Market size was valued at USD 1,819.3 million in 2023 and poised to grow at 7.1% CAGR from (2024-2030). PED is a viral disease of pigs characterized by serious diarrhoea, vomiting, and high mortality rates in piglets. As one of the key diseases with important economic ramifications for the swine sector, the development and use of vaccines are very important in controlling outbreaks and reducing losses. The frequent outbreaks of PED, particularly in large pork-producing regions, drive the demand for effective vaccines. The Chinese Ministry of Agriculture reports that China produces over 50% of the world's pork, highlighting the critical role of PED vaccines in maintaining industry stability. Also, growing awareness among swine producers about the benefits of vaccination is driving market demand.

However, the cost of vaccines may be prohibitive for small-scale swine producers, limiting market penetration in some regions. Also, variability in vaccine efficacy due to different PED virus strains can be a challenge in achieving widespread adoption. Whereas, the increasing swine production in emerging markets presents significant opportunities for vaccine manufacturers.

Porcine Epidemic Diarrhoea Vaccines Market Key Developments:

• In 2023: Zoetis was granted a patent for a new vaccine composition against PEDV. This vaccine utilizes novel nucleotide sequences to protect swine from various PEDV strains and is designed to be effective in both single and two-dose programs.